secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001193125-22-150187
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Coherus appoints Jill O'Donnell-Tormey, Ph.D. to board effective May 18, 2022
-----------------------------------------------------------------------------

- Board expanded from 7 to 8 directors; O'Donnell-Tormey appointed as Class II director, term through 2025 annual meeting.
- She is CEO of Cancer Research Institute since 1993; also serves on boards of CUNY, Richmond University Medical Center.
- Will receive $50,000 annual cash retainer and option for 54,000 shares vesting over three years.
- Appointed to the Nominating Committee of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312522150187/0001193125-22-150187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312522150187/d287872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer